Evaxion’s preclinical asset targets an unknown infectious disease in which there are no other vaccines available.

Patients will now be able to access BMS' Sotyktu for significantly cheaper than current list prices, alongside BMS and Pfizer ...

After demonstrating that its gene therapy can slash Huntington's disease progression by 75%, Uniqure will now file for ...

Moderna has opened its new vaccine manufacturing and R&D facility in Oxfordshire, UK, the Moderna Innovation and Technology ...

Sanofi has committed an additional $625m to its venture capital arm, Sanofi Ventures, bringing its total assets under ...

Data at ECTRIMS will help back fenebrutinib as a potential addition to Roche’s arsenal of drugs, and help cement Ocrevus’s ...

The contract replaces BARDA’s agreement with Venatorx, the company that licensed the oral antibiotic to Basilea.

As Eli Lilly and Novo Nordisk await approval of their oral GLP-1RAs, the healthcare editorial team discuss data and market opportunity.

Daiichi Sankyo and AstraZeneca have received priority review from the US Food and Drug Administration (FDA) for Enhertu plus ...

The API facility, which will make orforglipron amongst other small molecules, is part of Eli Lilly’s $27bn US manufacturing ...

Lilly plans to invest $6.5bn in an active pharmaceutical ingredients (API) manufacturing facility at Generation Park in ...

There’s been another detour in tolebrutinib’s path to market, with developer Sanofi revealing that the US Food and Drug ...